Research Paper

Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents

Volume 12, Issue 3   August 1, 2011
Pages 229 - 238
http://dx.doi.org/10.4161/cbt.12.3.17033
Authors: Wenge Wang, Jean-Nicolas Gallant, Sharyn I. Katz, Nathan G. Dolloff, Charles D. Smith, Junaid Abdulghani, Joshua E. Allen, David T. Dicker, Bo Hong, Arunasalam Navaraj and Wafik S. El-Deiry

View affiliations

Preview



Abstract:

Quinacrine has been widely explored in treatment of malaria, giardiasis, and rheumatic diseases. We find that quinacrine stabilizes p53 and induces p53-dependent and independent cell death. Treatment by quinacrine alone at concentrations of 10–20 mM for 1–2 d cannot kill hepatocellular carcinoma cells, such as HepG2, Hep3B, Huh7, which are also resistant to TRAIL. However, quinacrine renders these cells sensitive to treatment by TRAIL. Co-treatment of these cells with quinacrine and TRAIL induces overwhelming cell death within 3–4 h. Levels of DR5, a pro-apoptotic death receptor of TRAIL, are increased upon treatment with quinacrine, while levels of Mcl-1, an anti-apoptotic member of the Bcl-2 family, are decreased. While the synergistic effect of quinacrine with TRAIL appears to be in part independent of p53, knockdown of p53 in HepG2 cells by siRNA results in more cell death after treatment by quinacrine and TRAIL. The mechanism by which quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapies, and the potential for clinical application currently are being further explored. Lastly, quinacrine synergizes with chemotherapeutics, such as adriamycin, 5-FU, etoposide, CPT11, sorafenib, and gemcitabine, in killing hepatocellular carcinoma cells in vitro and the drug enhances the activity of sorafenib to delay tumor growth in vivo.

Advertisements